ONK’s most advanced candidate is ONKT101, which targets CD19 and features a membrane bound DR5 TRAIL variant. First-generation CAR-T cell therapies have shown the potential of targeting CD19 to ...

We used TRA-8 to examine the cell-surface expression of DR5 in a panel of human tumor cells and to determine the susceptibility of these cells to both TRAIL- and TRA-8–mediated apoptosis.